PYC achieves key designation for drug aiming to treat blinding eye disease ADOA
PYC Therapeutics Ltd has received a special designation from the FDA for its drug PYC-001 to treat a childhood-originating eye disease.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.